Study details
Enrolling now
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Iovance Biotherapeutics, Inc.
NCT IDNCT07288203ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
100
Study length
about 8.1 years
Ages
18–70
Locations
1 site in TN
About this study
This trial is testing a treatment called lifileucel, which are tumor-infiltrating lymphocytes (TILs), in adults with advanced melanoma. This is a Phase 2 trial for participants who have previously received treatment for unresectable or metastatic melanoma.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Lifileucel
PhasePhase 2
DrugLifileucel
Primary goalObjective Response Rate
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
lifileucel
Endpoints
Primary: Objective Response Rate
Secondary: Adverse Events, Complete Response Rate, Disease Control Rate, Duration of Response, Objective Response Rate, Overall Survival, Progression-Free Survival
Body systems
Oncology